Oppenheimer Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

United Therapeutics (NASDAQ:UTHR) had its price objective upped by Oppenheimer from $575.00 to $600.00 in a research note published on Thursday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

UTHR has been the topic of several other reports. Wells Fargo & Company boosted their price objective on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday. Morgan Stanley set a $447.00 target price on United Therapeutics in a research report on Wednesday, October 29th. Royal Bank Of Canada raised their price target on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a research report on Wednesday, November 19th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $533.55.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $503.60 on Thursday. The stock has a 50 day moving average price of $484.64 and a 200-day moving average price of $444.51. United Therapeutics has a one year low of $266.98 and a one year high of $537.19. The company has a market capitalization of $21.69 billion, a P/E ratio of 18.05, a P/E/G ratio of 2.85 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the business earned $6.19 earnings per share. United Therapeutics’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00. Following the completion of the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,908,078.58. This represents a 72.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 407,954 shares of company stock worth $197,601,528. Insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

A number of hedge funds have recently bought and sold shares of UTHR. Avoro Capital Advisors LLC increased its holdings in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC grew its stake in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Invesco Ltd. grew its stake in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and reiterated growth ambition — United Therapeutics reported $7.70 EPS (vs. $6.78 expected) and posted record full‑year revenue of $3.18B, supporting upside momentum. Read More.
• Positive Sentiment: Analysts raised price targets materially — H.C. Wainwright (PT to $600, buy), Oppenheimer (PT to $600, outperform) and RBC (PT to $643, outperform) lifted targets after the print, adding potential upside for the stock. Read More. Read More. Read More.
• Positive Sentiment: Management is targeting a ~$4B revenue run‑rate by 2027 tied to upcoming product launches — a clear multi‑year growth thesis that supports analyst optimism. Read More.
• Neutral Sentiment: Bullish options flow around the print — elevated call buying suggests traders were positioning for upside or volatility, which can amplify moves but is not a fundamental change. Read More.
• Neutral Sentiment: Analyst views remain mixed — some firms (BTIG, Morgan Stanley) kept Hold ratings and Morgan Stanley’s $447 target signals caution even as others raise targets, so expect divergent analyst notes ahead. Read More.
• Negative Sentiment: Revenue missed the quarter — $790.2M vs. ~ $814.8M consensus, which prompted earlier weakness and highlights top‑line execution risk. Read More.
• Negative Sentiment: Significant insider selling — the COO sold large blocks (14,440 shares) and a director sold additional lots in February; repeated insider disposals can undermine confidence even if they may be for diversification. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.